1 |
Kollins SH, McClernon FJ, Fuemmeler BF. Association between smoking and attention-deficit/hyperactivity disorder symptoms in a population-based sample of young adults. Arch Gen Psychiatry. 2005;62:1142-7.
DOI
|
2 |
Heishman SJ, Kleykamp BA, Singleton EG. Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology. 2010;210:453-69.
DOI
|
3 |
Jain R, Varma S, Mohan D. Effects of selective dopaminergic drugs in nicotine tolerant rats. Drug Alcohol Depend. 2001;63:72.
|
4 |
Hopkins TJ, Rupprecht LE, Hayes MR, Blendy JA, Schmidt HD. Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats. Neuropsychopharmacology. 2012;37:2310-21.
DOI
|
5 |
Kushner HI. Toward a cultural biology of addiction. BioSocieties. 2010;5(1):8-24.
DOI
|
6 |
Addicott MA, et al. Smoking withdrawal is associated with increases in brain activation during decision making and reward anticipation: a preliminary study. Psychopharmacology (Berl). 2012;219(2):563-73
DOI
|
7 |
Gotti C, Clementi F, Fornari A, Gaimarri A, Guiducci S, Manfredi I, et al. Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem Pharmacol. 2009;78:703-11.
DOI
|
8 |
Satoshi I. Brain reward circuitry beyond the mesolimbic dopamine system: A neurobiological theory. Neurosci Biobehav Rev. 2010;35(2): 129-50.
DOI
|
9 |
Christopher C Lapish, Sven K, Daniel D, Antonieta L, Jeremy K Seamans. The ability of the mesocortical dopamine system to operate in distinct temporal modes. Psychopharmacology. 2007;191(3): 609-25.
DOI
|
10 |
Centers for Disease Control and Prevention (US); National Center for Chronic Disease Prevention and Health Promotion (US); Office on Smoking and Health (US). How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention (US); 2010. 4, Nicotine Addiction: Past and Present.
|
11 |
Christian L, Mark AU. The Mechanistic Classification of Addictive Drugs. PLoS Med. 2006;3(11):e437.
DOI
|
12 |
Bryon AD. Neurobiological Processes in Drug Reward and Addiction. Harv Rev Psychiatry. 2004;12(6):305-20.
DOI
|
13 |
Alfred JR, Eric JN. Transcriptional and Epigenetic Mechanisms of Addiction. Nat Rev Neurosci. 2011;12(11):623-37.
DOI
|
14 |
Hugo JO, David CG, Ernestina HG, Gerardo BM. The Role of Dopamine and Its Dysfunction as a Consequence of Oxidative Stress. Oxid Med Cell Longev. 2016;2016: 9730467.
|
15 |
Buchta WC, Riegel AC. Chronic cocaine disrupts mesocortical learning mechanisms. Brain Research. 2015;631-5.
DOI
|
16 |
Salas R, Cook KD, Bassetto L, De Biasi M. The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice. Neuropharmacology. 2004; 47(3):401-7.
DOI
|
17 |
Deutch AY, Roth RH. The determinants of stress-induced activation of the prefrontal cortical dopamine system. Progress in Brain Research. 1990;85:367-403.
DOI
|
18 |
Schmitt KC, Rothman RB, Reith ME. Nonclassical pharmacology of the dopamine transporter: atypical inhibitors, allosteric modulators, and partial substrates. Journal of Pharmacology and Experimental Therapeutics. 2013;346(1):2-10.
DOI
|
19 |
Calabresi P, Picconi B, Tozzi A, Di Filippo M. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends in Neurosciences. 2007;30(5):211-9
DOI
|
20 |
Bernard LF, Steven RG. Effects of nicotine in experimental animals and humans: an update on addictive properties. Handb Exp Pharmacol. 2009; (192): 335-67.
|
21 |
Neal LB. Pharmacology of Nicotine: Addiction, Smoking-Induced Disease, and Therapeutics. Annu Rev Pharmacol Toxicol. 2009; 49:57-71.
DOI
|
22 |
Charles RW, Michael JM, Sharon RG. Effectiveness of Nicotinic Agonists as Desensitizers at Presynaptic - and -Nicotinic Acetylcholine Receptors. Nicotine Tob Res. 2014;16(3): 297-305.
DOI
|
23 |
Arthur L.B, Alexey G.M, Michael SM, Trinh L, Meaghan N, Lidia L, Jennifer S, Catherine AS, Jed ER, Mark AM. Brain Nicotinic Acetylcholine Receptor Availability and Response to Smoking Cessation Treatment A Randomized Trial. JAMA Psychiatry. 2014;71(7):797-805.
DOI
|
24 |
Rachel EP, Robin AJL. Cellular Events in Nicotine Addiction Semin Cell Dev Biol. 2009;20(4): 418-31.
DOI
|
25 |
Wang H, Sun X. Desensitized nicotinic receptors in brain. Brain Res Brain Res Rev. 2005;48(3):420-37.
DOI
|
26 |
Yates SL, Bencherif M, Fluhler EN, Lippiello PM. Up-regulation of nicotinic acetylcholine receptors following chronic exposure of rats to mainstream cigarette smoke or alpha 4 beta 2 receptors to nicotine. Biochem Pharmacol. 1995;50(12):2001-8.
DOI
|
27 |
Laura M, Emanuele S, Enrico C. Regulation of GABA release by nicotinic acetylcholine receptors in the neonatal rat hippocampus. J Physiol. 2001;536(Pt 1): 89-100.
DOI
|
28 |
Nick C, Ortiz BA, Heidi C, O'Neill, Michael J, Marks, et al. Varenicline Blocks -nAChR-Mediated Response and Activates -nAChR-Mediated Responses in Mice In Vivo Nicotine. Tob Res. 2012;14(6): 711-9.
DOI
|
29 |
Goshman LM. Clinical Toxicology of Commercial Products. Journal of Pharmaceutical Sciences. 1985;74:1139-55.
DOI
|
30 |
Tiwari RK, Shukla SS, Roy A, Satapathy T, Pandey R. Role of Serotonin in Relapse to Nicotine addiction: An Overview. Advance Research in Pharmaceuticals & Biologicals. 2012;2(II):157-66.
|
31 |
Cunha OT, Rego AC, Oliveira CR. Cellular and molecular mechanisms involved in the neurotoxicity of opioid and psychostimulant drugs. Brain Res Rev. 2008;58(1):192-208.
DOI
|
32 |
Zhu PJ, Chiappinelli VA. Nicotine modulates evoked GABAergic transmission in the brain. J Neurophysiol. 1999;82:3041-5.
DOI
|
33 |
Perkins K, Stitzer M, Lerman C. Medication screening for smoking cessation: a proposal for new methodologies. Psychopharmacology. 2006;184(3-4):628-36.
DOI
|
34 |
Hurst R, Rollema H, Bertrand D. Nicotinic acetylcholine receptors: from basic science to therapeutics. Pharmacol Ther. 2013;137:22-54.
DOI
|
35 |
Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. European journal of pharmacology. 2000;393(1):295-314-344.
DOI
|
36 |
Bardo MT, Green TA, Crooks PA, Dwoskin LP. Nornicotine is self-administered intravenously by rats. Psychopharmacology. 1999;146(3):290-6.
DOI
|
37 |
Jin HP, Soo K, Areum D, Ji HK, Ah JK. Symptomatic bradycardia due to nicotine intoxication. Rev Bras Ter Intensiva. 2018; 30(1):121-6.
DOI
|
38 |
Danyan M, Keith G, Daniel S, Mc Gehee. Nicotine potentiation of excitatory inputs to VTA dopamine neurons J Neurosci. 2011; 31(18): 6710-20.
DOI
|
39 |
Pidoplichko VI, DeBiasi M, Williams JT, Dani JA. Nicotine activates and desensitizes midbrain dopamine neurons. Nature. 1997;390(6658):401-4.
DOI
|
40 |
Jain R, Mukherjee K. Biological basis of nicotine addiction. Indian Journal of Pharmacology. 2003;35:281-9.
|
41 |
Jiloha RC. Biological basis of tobacco addiction: Implications for smoking-cessation treatment. Indian J Psychiatry. 2010;52(4):301-7
DOI
|
42 |
Galindo CL, Hernandez LS, Galarraga E, Tapia D, Bargas J, Garduno J, et al. Serotoninergic dorsal raphe neurons possess functional postsynaptic nicotinic acetylcholine receptors. Synapse. 2008; 62(8):601-15.
DOI
|
43 |
Munir GK, Thomas JG. Nicotine Modulation of Fear Memories and Anxiety: Implications for Learning and Anxiety Disorders. Biochem Pharmacol. 2015; 97(4):498-511.
DOI
|
44 |
Yue X, Edward FD. Tobacco/Nicotine and Endogenous Brain Opioids Prog Neuropsychopharmacol. Biol Psychiatry. 2008;32(5): 1131-8.
|
45 |
Meaghan C, Creed NRN, Kelly RT. VTA GABA neurons modulate specific learning behaviors through the control of dopamine and cholinergic systems. Front Behav Neurosci. 2014;8:8.
DOI
|
46 |
George EB, Alexander I, Valentina EM. Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's disease. Front Aging Neuro-sci. 2014; 6: 340.
|
47 |
Bierut LJ, Stitzel JA, Wang JC, Hinrichs AL, Grucza RA, Xuei X, et al. 2008. Variants in nicotinic receptors and risk for nicotine dependence. Am J Psychiatry. 165:1163-71.
DOI
|
48 |
Joanna SF, Nora DV, Gene JW, Naomi P, Jean L, Colleen S, et al. Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci U S A. 1996;93(24):14065-9.
DOI
|
49 |
Tyndale RF, Pianezza ML, Sellers EM. A common genetic defect in nicotine metabolism decreases risk for dependence and lowers cigarette consumption. Nicotine Tob Res. 1999; 1(Suppl 2):S63-7.
|
50 |
Julie AT, Jeffrey AH, Dedra B, Barbara VH, Patricia NH, Rachel FT. Variation in CYP2A6 and nicotine metabolism among two American Indian tribal groups differing in smoking patterns and risk for tobacco-related cancer. Pharmacogenet Genomics. 2017; 27(5):169-78.
DOI
|
51 |
Johnstone EC, Yudkin PL, Hey K, et al. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics. 2004;14(2):83-90.
DOI
|
52 |
Neal LB. Pharmacology of Nicotine: Addiction, Smoking-Induced Disease, and Therapeutics. Annu Rev Pharmacol Toxicol. 2009;49:57-71.
DOI
|